Stay updated on Nivolumab Switch for Metastatic Renal Cell Carcinoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab Switch for Metastatic Renal Cell Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab Switch for Metastatic Renal Cell Carcinoma Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The page now presents the ClinicalTrials.gov record for the NIVOSWITCH phase II study, comparing nivolumab with continued tyrosine kinase inhibitor therapy for advanced or metastatic renal cell carcinoma. It includes the trial’s terminated status and detailed study, participant, and outcome information.
    Difference
    57%
    Check dated 2026-11-08T15:10:13.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    The site footer revision label changed from v3.7.2 to v3.8.0 while the study page continued to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T16:13:28.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    A notice appears above the study record stating that NIH is transitioning from the term “Artificial Intelligence” to “Super Intelligence.” The study record itself remains an error page.
    Difference
    1%
    Check dated 2026-10-25T15:25:01.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.1 to v3.7.2. The page remains a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-18T22:35:35.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The footer’s site revision identifier changes from v3.7.0 to v3.7.1, while the page continues to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-11T22:30:45.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error instead of the study record, indicating restricted access. The error page includes the standard header and footer, with a 403 message where the study details would appear.
    Difference
    0.6%
    Check dated 2026-09-27T22:45:33.000Z thumbnail image

Stay in the know with updates to Nivolumab Switch for Metastatic Renal Cell Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab Switch for Metastatic Renal Cell Carcinoma Clinical Trial page.